GeneHarmoni Bio Completes Tens of Millions RMB in Angel Funding to Build a World-Leading Enzyme-Electro Coupling Technology Platform

VCBeat has learned that Shenzhen OxSyns Technology Co., Ltd. (hereinafter referred to as “OxSyns”) has announced the completion of its angel round of financing. This round of financing was led byCDH VGCandTHE TRUE ONELead investor,Guohong JiaxinandInno Angel FundCo-investment.

OxSyns Technology Co., Ltd.Established in November 2022, OxSyns Technology Co., Ltd. is a global pioneer in the research and development of enzyme-electrode coupling technology. The founding team, all hailing from the University of Oxford, possesses extensive combined expertise in technological R&D and commercial incubation. The team returned to China to launch the venture after securing first place in the University of Oxford Entrepreneurship Competition. The company has since received numerous accolades, including First Prize in the China Nanotechnology Competition, the Excellence Award in the Ministry of Education’s Chunhui Cup, Second Prize in the SCIP Green Chemistry Innovation Competition, Third Prize in the HICOOL Global Entrepreneurship Competition, and recognition as one of the Top 10 Nationwide Innovations in “Sci-Tech China 2023.” OxSyns currently operates R&D centers in Shenzhen and Beijing, with interdisciplinary capabilities in nanomaterial development, electrochemical catalysis, and bioengineering, and maintains a pilot-scale experimental platform in Shanghai.

The Company's UniqueCell-Free Enzymatic Electrocatalysis TechnologyIt will serve as “next-generation synthetic biology technology,” profoundly impacting the development of the synthetic biology industry.

Leveraging the technological platforms of OxSyns Technology for enzyme engineering and optimization, as well as electrochemistry,OxSyns Technology Co., Ltd. offers universal, flexible, modular, and low-carbon solutions in electro-enzymatic catalytic synthesis.Features, capable of providing diverse high-value-added raw materials for fields such as life sciences.

OxSyns Technology’s cell-free catalytic platform enables multi-enzyme co-immobilization, continuous-flow reactions, and efficient cofactor recycling. Notably, its electrically driven cofactor recycling system reduces cofactor consumption by more than fivefold compared to current mainstream technologies.The entire catalytic system maintains high catalytic conversion efficiency over extended periods, while featuring unique real-time monitoring via electrical signals. This significantly boosts productivity in molecular synthesis and delivers comprehensive cost advantages. The company’s technological optimization of cofactor recycling has substantially reduced costs, effectively enhancing the economic viability of scaling up synthetic biology to industrial levels and breaking through the bottlenecks hindering the industrialization of cell-free biomanufacturing.

Meanwhile, by leveraging the electrical signal representation of biological information based on technological implementation, efficient and real-time detection of biochemical indicators can be achieved. The company has successfully validated the detection of multiple biochemical markers using this technology. Through this approach, certain biochemical indicators that previously required chemiluminescence or electrochemical methods with added electron mediators can now be detected via direct electron transfer, demonstrating higher sensitivity and responsiveness. This enzymatic electrochemical sensing technology is poised to achieve breakthroughs in the field of innovative medical devices, offering more precise, convenient, and safe solutions for medical diagnosis and treatment.